Do you want to link to this Amgen Site outside the UK and leave amgeninflammation.co.uk?
YOU ARE NOW LEAVING THIS WEBSITE. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.
Cytotoxic T lymphocyte (CTL) cells, also known as CD8+ T cells, are immune cells that destroy any cell thought to be a threat to the integrity of the host, from virally infected cells to spontaneous tumors.1 CTLs offer protection against intracellular pathogens by killing the infected cell before the pathogens can proliferate and further infect the neighboring cells.2
Activation of naïve CTLs to effector cells is required prior to these cells exerting their cytotoxic potential.2 CTLs comprise a distinct lymphocyte class that responds to various stimuli such as major histocompatibility antigens, protein antigens, viruses, as well as intracellular bacteria and parasites. These cells recognize peptides bound to the MHC class I molecules, and exposure to specific antigens results in the activation and proliferation of CTLs. Activated CTLs secrete cytolytic mediators (eg, perforin) and also cause target cell apoptosis.3 CTLs kill the target cells via cell-cell interactions or secretion of cytokines (IFN-γ and TNF-α).1 Cytokine secretion enhances antigen presentation and mediation of antipathogenic effects.3 CTL reorganizes its cytoskeleton to focus its killing apparatus on the target cell and avoids killing neighboring cells by secreting its toxic proteins into a confined space.2
CTLs perform an important function of destroying intracellular pathogens or cancer cells, and disease control can be achieved by modulation of CTL production or activation.3 Derangements in CTLs result in autoimmune diseases (including autoimmune skin disorders), neoplastic disease, and possibly allergic contact dermatitis.1
APC: antigen-presenting cell; CD: cluster of differentiation; IFN-γ: interferon gamma; MHC: major histocompatibility complex; TNF: tumor necrosis factor.
Adverse events should be reported. Reporting forms and information can be found for the UK at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or for Ireland at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events and product complaints should also be reported to Amgen Limited on +44 (0)1223 436441 (UK and Northern Ireland) or Freephone 1800 535 160 (Ireland)